Alternative treatments are needed to curb off-label AP use among community-dwelling older adults, given the high prevalence of cardiovascular disease and stroke. Monitoring guidelines are needed to promote safer prescribing practices.
Majuri et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: